Usana Health Sciences (USNA) Cost of Revenue (2010 - 2026)

Usana Health Sciences (USNA) has 17 years of Cost of Revenue data on file, last reported at $59.4 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 13.33% year-over-year to $59.4 million in Q2 2026; TTM through Apr 2026 was $207.8 million, a 21.84% increase from a year earlier, with the FY2026 full-year figure at $200.9 million, up 24.59% from the prior year.
• Cost of Revenue for Q2 2026 stood at $59.4 million, up from $49.4 million in the prior quarter.
• Over the last five years, Cost of Revenue for USNA reached as high as $67.8 million in Q1 2022 and fell as low as $38.6 million in Q4 2024.
• Historically, Cost of Revenue has averaged $47.8 million across 5 years, with a median of $47.5 million in 2022.
• Across the five-year window, Cost of Revenue plunged 31.53% in 2022 and increased 28.16% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $46.4 million in 2022, then retreated by 8.85% to $42.3 million in 2023, then slipped by 8.9% to $38.6 million in 2024, then advanced by 26.62% to $48.8 million in 2025, then rose by 21.76% to $59.4 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $59.4 million in Q2 2026, $49.4 million in Q1 2026, and $48.8 million in Q3 2025.